Literature DB >> 17620074

Allergen-induced in vitro expression of IL-18, SLAM and GATA-3 mRNA in PBMC during sublingual immunotherapy.

J Savolainen1, K Nieminen, K Laaksonen, T Laiho, L Jacobsen, R Lahesmaa, E O Terho, E Valovirta.   

Abstract

BACKGROUND: Signalling lymphocytic activation molecule (SLAM) and interleukin (IL)-18 induce interferon (IFN)-gamma production from Th1 cells. The allergen-induced SLAM and IL-18 mRNA expressions are increased during subcutaneous immunotherapy (SCIT), but nothing is known about their role during sublingual immunotherapy (SLIT). Transcription factor GATA-3 is associated with Th2 cells but its role in SCIT and SLIT is yet unexplored. This study was undertaken to analyse the allergen induced in vitro mRNA expression of IL-18, SLAM and GATA-3 in peripheral blood mononuclear cells (PBMC) of children with allergic rhinitis (AR) during SLIT.
METHODS: Ten patients with AR undergoing pollen SLIT with a weekly dose of 200,000 SQ-U, 10 with 24,000 SQ-U of mixture of Betula verrucosa, Corylus avellana and Alnus glutinosa and 10 with placebo were included. Peripheral blood mononuclear cell were stimulated with birch extract prior to, after 1 and 2 years of the treatment. The mRNA expression was assessed using kinetic real-time RT-PCR (TaqMan); Applied Biosystems, Foster City, CA, USA).
RESULTS: The expression of IL-18 mRNA was increased in the high-dose group in comparison to the placebo group after 1 year of therapy (P = 0.028) and had an inverse correlation with the late phase skin reaction after the second study year (r = -0.41, P = 0.041). SLAM mRNA expression increased in the high-dose group from baseline to 1 year (P = 0.028) and correlated with IL-10 (r = 0.96, P < 0.0001) and transforming growth factor-beta (r = 0.80, P = 0.0037) mRNA expression. No significant changes were seen in GATA-3 mRNA expression.
CONCLUSIONS: During SLIT, IL-18 and SLAM are upregulated, suggesting that the Th2 type inflammatory response is downregulated during SLIT by increased Th1 type response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17620074     DOI: 10.1111/j.1398-9995.2007.01426.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  6 in total

1.  Sub-lingual immunotherapy: world allergy organization position paper 2009.

Authors:  G Walter Canonica; Jean Bousquet; Thomas Casale; Richard F Lockey; Carlos E Baena-Cagnani; Ruby Pawankar; Paul C Potter; Philippe J Bousquet; Linda S Cox; Stephen R Durham; Harold S Nelson; Giovanni Passalacqua; Dermot P Ryan; Jan L Brozek; Enrico Compalati; Ronald Dahl; Luis Delgado; Roy Gerth van Wijk; Richard G Gower; Dennis K Ledford; Nelson Rosario Filho; Erkka J Valovirta; Osman M Yusuf; Torsten Zuberbier
Journal:  World Allergy Organ J       Date:  2009-11-19       Impact factor: 4.084

2.  Effect of sublingual immunotherapy on level of cytokines in PBMCs of patients with allergic asthma.

Authors:  Zhongxi Wang; Wenjing Li; Huan Chen; Wei Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-06-14

Review 3.  Allergen immunotherapy for allergic respiratory diseases.

Authors:  Antonio Cappella; Stephen R Durham
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

Review 4.  Allergic rhinoconjunctivitis: complementary treatments for the 21st century.

Authors:  Simi Kapoor; Leonard Bielory
Journal:  Curr Allergy Asthma Rep       Date:  2009-03       Impact factor: 4.806

Review 5.  Subcutaneous and sublingual immunotherapy in children: complete update on controversies, dosing, and efficacy.

Authors:  Désirée Larenas-Linnemann
Journal:  Curr Allergy Asthma Rep       Date:  2008-11       Impact factor: 4.806

6.  Sublingual immunotherapy in allergic rhinitis.

Authors:  Doo Hee Han; Chae-Seo Rhee
Journal:  Asia Pac Allergy       Date:  2011-10-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.